Julphar announces the official launch of its newly developed and locally manufactured full portfolio of insulin analogues

In the distinguished presence of more than 180 healthcare professionals, Julphar proudly announces the official launch of its newly developed and locally manufactured full portfolio of insulin analogues. This comprehensive range includes Insulin Aspart, a rapid-acting insulin; Insulin Aspart/Aspart Protamine, a premixed insulin formulation; and Insulin Glargine, a long-acting insulin, all tailored to address the diverse treatment needs of diabetes patients.

This milestone marks a significant step forward in Julphar’s strategic growth, reflecting our steadfast dedication to delivering advanced healthcare solutions and responding to the evolving needs of the diabetes community throughout the MENA region.

By strengthening and expanding our product offering, Julphar reaffirms its pioneering role as a trusted and enduring partner in improving outcomes for people living with diabetes.